Bromocriptine and Erythromycin Interaction

Understanding the Bromocriptine and Erythromycin Interaction

FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Bromocriptine belongs to the Dopamine Agonist (Diabetes) class and Erythromycin belongs to the Macrolide Antibiotic class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Erythromycin slows down how fast your body gets rid of bromocriptine. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Bromocriptine has 7 total documented interactions on file in this dataset, and Erythromycin has 63. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor may need to lower your dose of bromocriptine or watch you more closely for side effects while you are taking this antibiotic. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Bromocriptine or Erythromycin based on a web page, speak with your prescriber or pharmacist before making any change.